Biomarkers.

Background: AD-NeuroScore is a validated metric that summarizes Alzheimer's disease (AD)-specific atrophy and can detect AD early, benchmark disease severity, predict and monitor AD progression, and can aid in testing the efficacy of therapeutic interventions using a single number (Kress, 2023). It meets criteria for translatability by using clinically available regional brain volumes as input (Ahdidan, 2015; Cavedo, 2022) and having patient and model-level interpretability (Pinto, 2022). Also, features can be reviewed by a neuroradiologist (Larson, 2019).

Biomarkers.

Background: Brain aging (BA) involves the gradual deterioration of brain systems and is associated with chronological age (CA). Measures of BA have been validated and adopted in aging and neurological disease research (Biondo, 2022; Eickhoff, 2021) and could be a useful clinical tool. BA predicts CA in healthy adults (Cole, 2017) and accelerated BA precede Alzheimer's disease (AD) symptoms (Elliott, 2021).

Public Health.

Background: Alzheimer's disease (AD) presents a significant global health challenge, with limited pharmacological interventions available. Physical activity (PA) is a promising therapeutic approach for delaying AD onset and mitigating neuropathology. Only a handful of meta-analyses have explored the effects of exercise interventions on structural MRI (sMRI)-estimated brain volumes in adults with mixed cognitive statuses, two of which found positive effects on left and bilateral hippocampal volume (HV).

Public Health.

Background: Medical management and lifestyle are potentially crucial interventions for Alzheimer's disease (AD). In this study, we present the relationship between adherence of a personalized multi-modal intervention for AD on change in cerebral blood flow (CBF) after 12-months.

Methods: The PREVENTION study is an ongoing randomized clinical trial (McEwen, 2001).

Botulinum Toxin Application for Treatment of Graft Vasospasm: A Reverse Translational Study.

Vascular graft vasospasm is a lethal risk when using grafts for revascularization and reconstructive surgery. Revascularization is a treatment modality for ischemic diseases including Moyamoya disease that requires bypass surgery. Cerebrovascular graft transplantation carries a 5-10% risk of vasospasm, which can lead to devastating neurological sequelae.